TFX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TF

Mkt Cap

$5.53B

Volume

566.90K

Next Earnings

November 5th

Loading chart

TF

TFXTeleflex Incorporated

TFX

Pay with—

Available Balance0.00

TF

Mkt Cap

$5.53B

Volume

566.89K

Next Earnings

November 5th

Chart Financials Earnings News About Dividends Insider Filings

China Airway Management Market Forecast to 2033 - Airway Management Tubes and Intubation Accessories | Revenue, Volume, Pricing, Company Share, and Growth OpportunitiesResearchAndMarkets.com released a comprehensive market report on China's airway management sector, covering historical data from 2018 and forecasts through 2033. The report segments the market into Airway Management Tubes and Intubation Accessories, providing revenue, volume, and pricing analysis. It includes 2025 company share data and profiles of key competitors to support strategic planning and investment decisions in this growing medical device market.GlobeNewswire Inc. · Oct 9, 2026

Bruker Gains 66.3% in a Year: What's Driving the Rally?Bruker Corporation (BRKR) shares gained 66.3% over the past year, driven by strong demand in biopharma, diagnostics, and mass spectrometry. However, the company faces a $134.9M goodwill impairment, currency headwinds, and restructuring costs. Full-year 2026 revenue guidance was lowered to $3.54-$3.57B due to currency pressures, though the company maintains a solid financial position with $184.9M in cash.Zacks Investment Research · Oct 8, 2026

Reasons to Add Globus Medical Stock to Your Portfolio NowGlobus Medical (GMED) reported strong Q2 2026 performance with musculoskeletal revenues rising 7.5% and base business sales up 10.9%. The company continues to gain market share through product innovation, with over 60 development projects underway. However, foreign exchange volatility remains a concern. GMED maintains a debt-free balance sheet with $507.7 million in cash, supporting continued R&D and expansion investments.Zacks Investment Research · Oct 7, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally?Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 7, 2026

TFX or SONVY: Which Is the Better Value Stock Right Now?In a comparison of two Medical Instruments stocks, Teleflex (TFX) emerges as the better value opportunity compared to SONOVA HOLDING (SONVY). TFX has a superior Zacks Rank of #2 (Buy) versus SONVY's #3 (Hold), along with more attractive valuation metrics including a lower forward P/E ratio of 17.36 versus 21.87, a PEG ratio of 0.84 versus 2.42, and a P/B ratio of 1.91 versus 5.51. TFX earned a Value grade of B while SONVY received a D grade.Zacks Investment Research · Oct 6, 2026

Is It Prudent to Add Teleflex Stock to Your Portfolio Now?Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment.Zacks Investment Research · Oct 6, 2026

Boston Scientific's MedSurg Diversification Bolsters Growth ProspectsBoston Scientific's MedSurg segment showed mixed Q2 2026 results with Endoscopy growing 7% and Neuromodulation up 12%, but Urology disappointed with only 1% growth due to sacral neuromodulation recovery delays and stone management portfolio gaps. The company expects flat to low-single digit Urology growth for full-year 2026 but remains confident in 2027 improvement with planned product launches. BSX stock has underperformed the industry and carries a Zacks Rank #4 (Sell) rating.Zacks Investment Research · Sep 30, 2026

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for NowBio-Rad Laboratories (BIO) shows modest growth in Clinical Diagnostics with quality controls and blood typing leading, supported by strong international presence. However, China weakness, geopolitical volatility, and foreign exchange headwinds constrain full-year outlook. The company maintains a Hold rating with reaffirmed guidance of 3% decline to 0.5% growth for 2026.Zacks Investment Research · Sep 23, 2026

Is This the Right Time to Add DGX Stock to Your Portfolio?Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.Zacks Investment Research · Sep 22, 2026

Reasons to Retain Penumbra Stock in Your Portfolio for NowPenumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.Zacks Investment Research · Sep 16, 2026

to start trading

TF

TFXTeleflex Incorporated

TFX

Pay with—

Available Balance0.00

Your PositionYou don't own any TFX yet.

Related Tickers

Earnings

Dividends

Last · Aug 14Quarterly

Amount$0.34

Yield1.04%

Annual$1.36